---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-121833"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:48:02.449726+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Coya Therapeutics Q3 net loss $4.0M, cash $39.8M post-raise; positive AD data, new CEO

## Summary
- Net loss $4.0M in Q3 2024 (vs $3.4M prior); cash $31.1M (Sep) rose to $39.8M after capital raise.
- Positive LD IL-2 data in mild-moderate Alzheimer's from investigator-initiated Phase 2 presented at CTAD24; patents filed for COYA 301/GLP-1 combo.
- Arun Swaminathan appointed CEO effective Nov 1, 2024; Howard Berman transitions to Executive Chairman.
- Aligned with FDA on non-clinical data for COYA-302 Phase 2b ALS trial; eligible for $8.4M milestone from Dr. Reddy's upon IND acceptance and dosing.
- 2025 catalysts: additional AD data Q1, ALS biomarker data Q2, FTD data 2H, and COYA-302 IND for FTD expected in 2H.

## SEC filing metadata
- accession: 0000950170-24-121833
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000095017024121833/0000950170-24-121833-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000095017024121833/coya-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-121833
- JSON: https://secwatch.observer/filing/0000950170-24-121833.json
- Plain text: https://secwatch.observer/filing/0000950170-24-121833.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.